Respiratory syncytial virus, an ongoing medical dilemma: An expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials

Influenza and other Respiratory Viruses

Volumn 9, Issue 4, 2015, Pages 169-178

  Broadbent, Lindsay ^a   Groves, Helen ^a   Shields, Michael D ^a,b   Power, Ultan F ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL BELFAST HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

Respiratory syncytial virus; Respiratory syncytial virus antivirals; Respiratory syncytial virus prophylactic antibodies; Respiratory syncytial virus vaccines

Indexed keywords

ALS 008176; ALX 0171; ASVASIRAN; DANIRIXIN; GS 5806; GSK 3003891 A; MDT 637; MEDI 534; MEDI 557; MEDI 559; MEDI 7510; MEDI 8897; MOTAVIZUMAB; PLACEBO; REGN 2222; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RI 001; RSV 001; RV 568; UNCLASSIFIED DRUG; VIRUS VACCINE; WO 2010149745;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; NANOENGINEERING; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VACCINATION; VACCINE PRODUCTION; ANIMAL; GENETICS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; PHYSIOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIROLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 84930806483     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12313     Document Type: Article

References (86)

1. Nair H, Nokes DJ, Gessner BD et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375:1545-1555.
2. Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A 2013; 110:11133-11138.
3. Shaikh FY, Utley TJ, Craven RE et al. Respiratory syncytial virus assembles into structured filamentous virion particles independently of host cytoskeleton and related proteins. PLoS One 2012; 7:e40826.
4. Nair H, Brooks WA, Katz M et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011; 378:1917-1930.
5. Lotz MT, Peebles RS. Mechanisms of respiratory syncytial virus modulation of airway immune responses. Curr Allergy Asthma Rep 2012; 12:380-387.
6. Feikin DR, Njenga MK, Bigogo G et al. Viral and bacterial causes of severe acute respiratory illness among children aged less than 5 years in a high malaria prevalence area of western Kenya, 2007-2010. Pediatr Infect Dis J 2013; 32:e14-e19.
7. Nicholson KG, McNally T, Silverman M, Simons P, Stockton JD, Zambon MC. Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine 2006; 24:102-108.
8. Moore HC, Jacoby P, Hogan AB, Blyth CC, Mercer GN. Modelling the seasonal epidemics of respiratory syncytial virus in young children. PLoS One 2014; 9:e100422.
9. Bawage SS, Tiwari PM, Pillai S, Dennis V, Singh SR. Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus. Adv Virol 2013; 2013:595768.
10. McNamara PS, Smyth RL. The pathogenesis of respiratory syncytial virus disease in childhood. Br Med Bull 2002; 61:13-28.
11. Hall CB, Powell KR, MacDonald NE et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986; 315:77-81.
12. Nair H, Verma VR, Theodoratou E et al. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children. BMC Public Health 2011; 11(Suppl 3):S30.
13. Mori M, Morio T, Ito S et al. Risks and prevention of severe RS virus infection among children with immunodeficiency and Down's syndrome. J Infect Chemother 2014; 20:455-459.
14. Hartling L, Bialy LM, Vandermeer B et al. Epinephrine for bronchiolitis. Cochrane Database Syst Rev 2011; 2004:CD003123.
15. Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev 2014; 6:CD001266.
16. Fernandes RM, Hartling L. Glucocorticoids for acute viral bronchiolitis in infants and young children. JAMA 2014; 311:87-88.
17. ICTRP Search Portal [Internet]. Available at http://apps.who.int/trialsearch/Default.aspx (Cited 1 February 2015).
18. Home - PubMed - NCBI [Internet]. Available at http://www.ncbi.nlm.nih.gov/pubmed/ (Cited 1 February 2015).
19. Power UF. Respiratory syncytial virus (RSV) vaccines-two steps back for one leap forward. J Clin Virol 2008; 41:38-44.
20. Haynes LM. Progress and challenges in RSV prophylaxis and vaccine development. J Infect Dis 2013; 208(Suppl):S177-S183.
21. Hall CB, Geiman JM, Biggar R, Kotok DI, Hogan PM, Douglas GR. Respiratory syncytial virus infections within families. N Engl J Med 1976; 294:414-419.
22. Henderson FW, Collier AM, Clyde WA, Denny FW. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979; 300:530-534.
23. Eick A, Karron R, Shaw J et al. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr Infect Dis J 2008; 27:207-212.
24. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003; 21:3479-3482.
25. Wright PF, Karron Ra, Belshe RB et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182:1331-1342.
26. Wright PF, Karron Ra, Belshe RB et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 2007; 25:7372-7378.
27. Karron Ra, Wright PF, Crowe JE et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 1997; 176:1428-1436.
28. Kim HW, Arrobio JO, Pyles G et al. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus. Pediatrics 1971; 48:745-755.
29. Karron RA, Thumar B, Schappell E, Buchholz UJ, Collins PL. Attenuation of live respiratory syncytial virus vaccines is associated with reductions in levels of nasal cytokines. J Infect Dis 2013; 207:1773-1779.
30. Wright PF, Karron Ra, Madhi Sa et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis 2006; 193:573-581.
31. Karron Ra, Wright PF, Belshe RB et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005; 191:1093-1104.
32. Meng J, Lee S, Hotard AL, Moore ML. Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes. MBio 2014; 5:e01704-e01714.
33. Luongo C, Winter CC, Collins PL, Buchholz UJ. Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature. J Virol 2013; 87:1985-1996.
34. Malkin E, Yogev R, Abughali N et al. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age. PLoS One 2013; 8:e77104.
35. IMPAACT P1114 (DAIDS ID 11948) A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV # 005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Mon. 2014 Available at http://impaactnetwork.org/studies/P1114.asp (accessed 01 February 2015)
36. Bermingham a, Collins PL. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci U S A 1999; 96:11259-11264.
37. Tang RS, Schickli JH, MacPhail M et al. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol 2003; 77:10819-10828.
38. González-Reyes L, Ruiz-Argüello MB, García-Barreno B et al. Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci U S A 2001; 98:9859-9864.
39. Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J 2012; 31:109-114.
40. Yang C-F, Wang CK, Malkin E et al. Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine. Vaccine 2013; 31:2822-2827.
41. Glenn GM, Smith G, Fries L et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013; 31:524-532.
42. Smith G, Raghunandan R, Wu Y et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One 2012; 7:e50852.
43. Glenn G, Raghunandan R, Lu H, Zhou B, Ngai K. Recombinant nanoparticle RSV F vaccine for respiratory syncytial virus: preclinical efficacy and clinical safety and immunogenicity. 2011. Available at https://www.novavax.com/download/file/presentations/RSV-F-Phase-1-Poster-2011_gs.pdf (accessed 01 February 2015).
44. Coler RN, Baldwin SL, Shaverdian N et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 2010; 5:e13677.
45. Swanson Ka, Settembre EC, Shaw Ca et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 2011; 108:9619-9624.
46. McLellan JS, Chen M, Joyce MG et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013; 342:592-598.
47. Magro M, Mas V, Chappell K et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci 2012; 109:3089-3094.
48. Baudoux GJMFP, Blais N, Cyr SL, Rheault P, Ruelle JL. Recombinant rsv antigens. Google Patents 2010.
49. Swedan S, Musiyenko A, Barik S. Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways. J Virol 2009; 83:9682-9693.
50. Oshansky CM, Krunkosky TM, Barber J, Jones LP, Tripp RA. Respiratory syncytial virus proteins modulate suppressors of cytokine signaling 1 and 3 and the type I interferon response to infection by a toll-like receptor pathway. Viral Immunol 2009; 22:147-161.
51. Oertel MD. RespiGam: an RSV immune globulin. Pediatr Nurs 1996; 22:525-528.
52. Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 2008; 12:iii, ix-x, 1-86.
53. Fouillard L, Mouthon L, Laporte JP et al. Severe respiratory syncytial virus pneumonia after autologous bone marrow transplantation: a report of three cases and review. Bone Marrow Transplant 1992; 9:97-100.
54. Weisman LE. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations. Curr Opin Mol Ther 2009; 11:208-218.
55. Ramilo O, Lagos R, Sáez-Llorens X et al. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J 2014; 33:703-709.
56. Kwakkenbos MJ, Diehl SA, Yasuda E et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med 2010; 16:123-128.
57. Robbie GJ, Criste R, Dall'acqua WF et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 2013; 57:6147-6153.
58. Human antibodies to respiratory syncytial virus f protein and methods of use thereof. 2014. Patent number: US20140271653 A1.
59. Gueller S, Duenzinger U, Wolf T et al. Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 2013; 15:435-440.
60. Turner TL, Kopp BT, Paul G, Landgrave LC, Hayes D, Thompson R. Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res 2014; 6:217-225.
61. Empey KM, Peebles RS, Kolls JK. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis 2010; 50:1258-1267.
62. Mackman RL, Sangi M, Sperandio D et al. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem 2015; 58:1630-1643.
63. DeVincenzo JP, Whitley RJ, Mackman RL et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014; 371:711-722.
64. Wong M-T, Chen SS-L. Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. Cell Mol Immunol 2014. doi: 10.1038/cmi.2014.127.
65. Karnati HK, Yalagala RS, Undi R, Pasupuleti SR, Gutti RK. Therapeutic potential of siRNA and DNAzymes in cancer. Tumour Biol 2014; 35:9505-9521.
66. Draz MS, Fang BA, Zhang P et al. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics 2014; 4:872-892.
67. Abdul-Wahab A, Qasim W, McGrath JA. Gene therapies for inherited skin disorders. Semin Cutan Med Surg 2014; 33:83-90.
68. DeVincenzo J, Cehelsky JE, Alvarez R et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008; 77:225-231.
69. DeVincenzo J, Lambkin-Williams R, Wilkinson T et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A 2010; 107:8800-8805.
70. Zamora MR, Budev M, Rolfe M et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011; 183:531-538.
71. Devincenzo J. Treatment with Oral ALS-008176, a Nucleoside Analog, Rapidly Reduces RSV Viral Load and Clinical Disease Severity in a Healthy Volunteer Challenge Study. IDWeek 2014. Idsa; 2014.
72. Van Bleek GM, Osterhaus ADME, de Swart RL. RSV 2010: recent advances in research on respiratory syncytial virus and other pneumoviruses. Vaccine 2011; 29:7285-7291.
73. Hultberg A, Temperton NJ, Rosseels V et al. Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PLoS One 2011; 6:e17665.
74. Depla E. ALX-0171: A Highly Potent Nanobody as Inhalation Treatment for Respiratory Syncytial Virus Infection. San Francisco: Next Generation Protein Therapeutics Summit, 2012.
75. Detalle L. Delivery of ALX-0171 by inhalation greatly reduces disease burden in a neonatal lamb RSV infection model. 9th RSV Symp, Stellenbosch, 2014.
76. Ackermann MR. Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments. ILAR J 2014; 55:4-15.
77. Depla E. Development pf ALX-0171, an Inhaled Nanobody for the Treatment of Respiratory Syncytial Virus Infection in Infants. Porto, Portugal: RSV Vaccines for the World Conference, 2013.
78. Bataki EL, Evans GS, Everard ML. Respiratory syncytial virus and neutrophil activation. Clin Exp Immunol 2005; 140:470-477.
79. Miller BE, Smart K, Mistry S et al. The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers. Eur J Drug Metab Pharmacokinet 2014; 39:173-181.
80. RV568, a narrow spectrum kinase inhibitor (NSKI), inhibits virus induced nasal interleukin-8 (IL8) in the human viral challenge model where healthy adult male volunteers were experimentally inoculated with live respiratory syncytial virus [Internet]. Available at http://erj.ersjournals.com/content/42/Suppl_57/1970.full.pdf (Cited 1 February 2015).
81. Cass L, Woodward K, Brindley C, Warrington S. Tolerability And Pharmacokinetic Profile Of RV568, A Narrow Spectrum Kinase Inhibitor, Following Single And Repeat Inhaled Dosing In Healthy Volunteers (ATS Journals). American Thoracic Society International Conference Meetings Abstracts.
82. Smyth RL, Mobbs KJ, O'Hea U, Ashby D, Hart CA. Respiratory syncytial virus bronchiolitis: disease severity, interleukin-8, and virus genotype. Pediatr Pulmonol 2002; 33:339-346.
83. DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis 2005; 191:1861-1868.
84. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, Devincenzo JP. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis 2011; 204:996-1002.
85. Wright PF, Gruber WC, Peters M et al. Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. J Infect Dis 2002; 185:1011-1018.
86. Fodha I, Vabret A, Ghedira L et al. Respiratory syncytial virus infections in hospitalized infants: association between viral load, virus subgroup, and disease severity. J Med Virol 2007; 79:1951-1958.